Soha Dolatabadi, MD
Internal Medicine · Los Angeles, CANPI 1992806277
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $290,014 of the $457,719 with a category attached, or 63.4%. 28 manufacturers reported payments, led by UCB, Inc. at 42.7% of the total. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,729 payments — averaging $264.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$195K
- Johnson & Johnson$130K
- GSK$39K
- AbbVie$33K
- Amgen$27K
- Novartis$19K
- plus $15K from 22 others
Across 1 payment — averaging $23,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$24K
What the payments were for
- Consulting fees$84,48218%
- Speaking & faculty fees$290,01463%
- Travel & lodging$45,41410%
- Food & beverage$37,4608%
- Education$3490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 368 | $195,337 |
| Johnson & Johnson | 300 | $130,248 |
| GSK | 135 | $38,674 |
| AbbVie | 195 | $32,637 |
| Amgen(2 entities) | 284 | $26,521 |
| Novartis | 123 | $19,440 |
| Janssen Scientific Affairs, LLC | 12 | $6,301 |
| Mallinckrodt Hospital Products Inc. | 53 | $2,397 |
| Lilly USA, LLC | 49 | $1,223 |
| AstraZeneca(2 entities) | 46 | $1,087 |
| Radius Health, Inc. | 30 | $591 |
| Aurinia Pharma U.S., Inc. | 12 | $568 |
| Pfizer | 20 | $479 |
| Boehringer Ingelheim | 12 | $471 |
| Bristol Myers Squibb | 28 | $451 |
| ANI Pharmaceuticals, Inc. | 19 | $402 |
| Hikma Pharmaceuticals USA | 13 | $225 |
| Actelion Pharmaceuticals US, Inc. | 6 | $158 |
| E.r. Squibb & Sons, L.L.C. | 7 | $121 |
| Sanofi | 4 | $104 |
| Fidia Pharma USA Inc. | 5 | $103 |
| Sobi, Inc | 2 | $56 |
| Genentech USA, Inc. | 1 | $27 |
| Fresenius Kabi USA, LLC | 1 | $26 |
| Tonix Medicines, Inc. | 1 | $24 |
| Celltrion USA Inc. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Alvogen Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$457,719 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 20 | $878,306 |
| RinvoqUpadacitinib | 88 | $594,207 |
| TremfyaGuselkumab | 35 | $486,645 |
| BenlystaBelimumab | 88 | $452,390 |
| Enbrel MiniEtanercept | 42 | $308,250 |
| KevzaraSarilumab | 70 | $282,897 |
| Orencia ClickjectAbatacept | 44 | $280,686 |
| XeljanzTofacitinib Citrate | 29 | $162,759 |
| Cimzia (2 Pack)Certolizumab Pegol | 23 | $140,628 |
| OtrexupMethotrexate/Pf | 172 | $133,163 |
| Enbrel SureclickEtanercept | 16 | $112,945 |
| ProliaDenosumab | 66 | $103,050 |
| ForteoTeriparatide | 21 | $99,534 |
| InflectraInfliximab-Dyyb | 22 | $97,120 |
| Evenity (2 Syringes)Romosozumab-Aqqg | 39 | $92,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $2,397 | $878,30620 claims |
| AbbVieRinvoq | $32,637 | $594,20788 claims |
| Johnson & JohnsonTremfya | $130,248 | $486,64535 claims |
| GSKBenlysta | $38,674 | $452,39088 claims |
| SanofiKevzara | $104 | $282,89770 claims |
| PfizerXeljanz, Inflectra | $479 | $259,88051 claims |
| AmgenProlia, Evenity (2 Syringes) | $26,521 | $195,520105 claims |
| Lilly USA, LLCForteo, Olumiant | $1,223 | $147,45936 claims |
| UCB, Inc.Cimzia (2 Pack) | $195,337 | $140,62823 claims |
| AstraZenecaSaphnelo | $1,087 | $73,80116 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $121 | $73,12014 claims |
| Alvogen IncTeriparatide | $11 | $50,87024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.